Pile of newspapers on white background

Blog

image-

LineaRx Signs Joint Development Agreement with Takis and Evvivax to Develop Linear-DNA Based Anti-Cancer Vaccines

Posted on

Collaboration Seeks to Develop PCR-produced Linear DNA as a Safer Expression Vector for Vaccines STONY BROOK N.Y., September 20, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement (the “Agreement”) with Takis […]

Read More email

image-

With New Spinoff, Biotech Goes All-In On DNA Sales

Posted on

SEPTEMBER 18, 2018 By GREGORY ZELLER A Stony Brook biotech with a growing international reputation for supply-chain security has spun off a new company focused on DNA modification and production. With an eye on exploding biotherapeutic fields, Stony Brook-based Applied DNA Sciences has spun its DNA-manufacturing business into a new company, LineaRx. Stony Brook-based Applied DNA […]

Read More email

image-

APDN Forms Subsidiary, LineaRx, to Develop DNA for Biotherapeutics

Posted on

STONY BROOK N.Y., September 18, 2018 – Applied DNA Sciences Inc., (NASDAQ: APDN, “Applied DNA” or the “Company”), the leader in large-scale PCR-based DNA manufacturing, announced today the formation of LineaRx, Inc., a wholly owned subsidiary. Its purpose is to commercialize the Company’s extensive experience in the design, manufacture and chemical modification of DNA by […]

Read More email

image-

APDN Presenting Linear DNA for Gene Therapy at Boston Immuno-Oncology Summit

Posted on

Applied DNA Presenting Linear DNA for Gene Therapy at Boston Immuno-Oncology Summit High-Expression Amplicons Facilitate Non-Recombinant Gene Therapies Hold the Potential to Serve as an Alternative to Plasmids and Viral Vectors STONY BROOK N.Y., August 27, 2018 – Applied DNA Sciences Inc., (NASDAQ: APDN, “Applied DNA,”), the leader in large-scale PCR-based DNA manufacturing, will present […]

Read More email